Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (88)

IV-01Christiane Dings

Mathematical modeling of the oral glucose tolerance test in pre-diabetic patients: An IMI DIRECT study

Thursday 15:25-16:50

IV-02Anne-Gaelle Dosne

Exposure-response analysis of erdafitinib and pharmacodynamic-guided dose individualization in patients with locally advanced or metastatic urothelial carcinoma

Thursday 15:25-16:50

IV-03Erwin Dreesen

A population pharmacokinetic and exposure-response model to support therapeutic drug monitoring during vedolizumab induction therapy

Thursday 15:25-16:50

IV-04Ronan Duchesne

Identifiability in nonlinear mixed effect models: the example of in vitro erythropoiesis

Thursday 15:25-16:50

IV-05Vincent Duval

A continuous-time Markov model (CTMM) for investigator’s global assessment (IGA) score in moderate-to-severe atopic dermatitis treated with subcutaneous nemolizumab.

Thursday 15:25-16:50

IV-06Dimitra Eleftheriadou

Aluminium biokinetics: Elucidating the speciation kinetics of the aluminium-citrate system in vitro.

Thursday 15:25-16:50

IV-07Douglas J. Eleveld

Aging and maturation as a reliability problem: The Weibull distribution and age- and maturation-adjustment functions

Thursday 15:25-16:50

IV-08Esther Encinas

Use of modeling and simulation methods to support the generic application of a vaginal delivery system

Thursday 15:25-16:50

IV-09Aline Engbers

Postnatal age, gestational age and small for gestational age drive the pharmacokinetics of ibuprofen enantiomers in very preterm neonates with patent ductus arteriosus

Thursday 15:25-16:50

IV-10Muhammad Faisal

Simultaneous semi-mechanistic population pharmacokinetic analysis of enalapril and enalaprilat in serum and urine following the administration of child appropriate oro-dispersible mini-tablets.

Thursday 15:25-16:50

IV-11Undine Falkenhagen

Structural model selection: Is the chi-square distribution appropriate for likelihood ratio tests?

Thursday 15:25-16:50

IV-12Alan Faraj

Drug effect of clofazimine on persisting mycobacteria explain an unexpected increase in bacterial load from patients

Thursday 15:25-16:50

IV-13Anam Fayyaz

Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes

Thursday 15:25-16:50

IV-14Anam Fayyaz

Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes

Thursday 15:25-16:50

IV-15Rebekka Fendt

Evaluating the benefit of individual patient data for physiologically based pharmacokinetic (PBPK) simulations

Thursday 15:25-16:50

IV-16Valentina Fermanelli

Correlation structure of Apolipoprotein A4, C3, E kinetics parameters

Thursday 15:25-16:50

IV-17Chiara Fornari

Importance of stability analysis when using non-linear semi-mechanistic models to describe drug-induced haematotoxicity

Thursday 15:25-16:50

IV-18Jose Francis

A semi-mechanistic model to characterise the influence of nevirapine- and lopinavir/ritonavir-based therapy on artemether and dihydroartemisinin exposure

Thursday 15:25-16:50

IV-19Yu Fu

Hemodynamic systems model to characterize cardiovascular drug effects

Thursday 15:25-16:50

IV-20Aline Fuchs

Assessment of translation of PKPD relationship from animal to human for malaria compounds

Thursday 15:25-16:50

IV-21Laura Fuhr

Physiologically based pharmacokinetic modeling of the dabigatran antidote idarucizumab

Thursday 15:25-16:50

IV-22Masato Fukae

Population pharmacokinetic modeling of esaxerenone: a novel nonsteroidal mineralocorticoid receptor blocker

Thursday 15:25-16:50

IV-23Fanny Gallais

Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies

Thursday 15:25-16:50

IV-24Fiona G. Gao

Prediction of human pharmacokinetics of subcutaneously administered insulin formulations

Thursday 15:25-16:50

IV-25Kamunkhwala Gausi

Pharmacokinetics of isoniazid preventative therapy among HIV-infected pregnant women in high tuberculosis incidence settings

Thursday 15:25-16:50

IV-26Sergey Gavrilov

Longitudinal assessment of tumor size and neutrophil count in multivariate joint models are more predictive of survival than their baseline values in patients with non-small cell lung cancer

Thursday 15:25-16:50

IV-27Peter Gennemark

Determination of antisense oligonucleotide tissue half-life

Thursday 15:25-16:50

IV-28Eva Germovsek

A time-to-event model relating integrated craving to risk of smoking relapse across different nicotine replacement therapy formulations

Thursday 15:25-16:50

IV-29Bill Gillespie

Torsten: Stan functions for pharmacometric applications. New functionality including within chain parallel computation.

Thursday 15:25-16:50

IV-30Anais Glatard

Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin levels using PK/PD modeling

Thursday 15:25-16:50

IV-31Ferran Gonzalez

Pharmacokinetic model development for total and free vancomycin in critically ill children

Thursday 15:25-16:50

IV-32Ignacio Gonzalez-Garcia

Pharmacokinetic/Pharmacodynamic Modelling of in vivo IL-13 Modulation by a monoclonal antibody (MEDI7836)

Thursday 15:25-16:50

IV-33Mario Gonzalez Sales

Assembling pharmacometric datasets in R: the puzzle package

Thursday 15:25-16:50

IV-34Katharina Martha Götz

Predictive Systems Medicine Modelling of Myelosuppression and Recovery of Hematopoietic Cells among Adult Patients with Hematopoietic Cell Transplantation

Thursday 15:25-16:50

IV-35Iztok Grabnar

Oxcarbazepine and its active metabolite 10-monohydroxycarbamazepine clearance maturation in paediatric patients with epilepsy

Thursday 15:25-16:50

IV-36Silvia Grandoni

Development and evaluation of a PBPK model to study the pharmacokinetics of inhaled drugs in rats

Thursday 15:25-16:50

IV-37Ana-Marija Grisic

Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study

Thursday 15:25-16:50

IV-38Jinju Guk

Modelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers

Thursday 15:25-16:50

IV-39Tingjie Guo

Exploring practical limitations of model-based Bayesian dose optimization in intensive care patients

Thursday 15:25-16:50

IV-40

Population pharmacokinetics of cannabidiol in healthy subjects

Thursday 15:25-16:50

IV-41Felix Hammann

Population pharmacokinetics and generation of dosing nomograms of daptomycin at a Swiss university hospital

Thursday 15:25-16:50

IV-42Lutz Harnisch

Dose Selection Process for Younger Children Participating in a Phase 3 Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-occlusive Crisis in Hospitalized Patients With Sickle Cell Disease

Thursday 15:25-16:50

IV-43Paul Healy

PKPD bridging and extrapolation of efficacy for the use of gabapentin and tramadol in paediatric chronic pain.

Thursday 15:25-16:50

IV-44Guenter Heimann

An Industry Perspective on Extrapolation in Pediatric Drug Development: A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy.

Thursday 15:25-16:50

IV-45Farina Hellmann

Population pharmacokinetic modelling in Ewing sarcoma patients focussing on etoposide as an example

Thursday 15:25-16:50

IV-46Emilie Hénin

Therapeutic drug monitoring strategies for Envarsus in de novo renal transplant patients using population modelling and simulations

Thursday 15:25-16:50

IV-47Charlotte Kloft

Review of NMLE articles published in clinical journals with a higher impact factor

Thursday 15:25-16:50

IV-48Thomas Henthorn

A population pharmacokinetic model of dense delta-9-tetrahydrocannabinol (THC), 11-OH-THC, and THCCOOH data and its use to estimate daily exposure in an observational cannabis study with sparse data

Thursday 15:25-16:50

IV-49Lukas Kovar

Physiologically-based pharmacokinetic (PBPK) modelling of nicotine and its main metabolite cotinine in healthy volunteers and smokers

Thursday 15:25-16:50

IV-50Anneke Himstedt

Prediction of pulmonary exposure based on plasma pharmacokinetics: A comparison of different model-based approaches.

Thursday 15:25-16:50

IV-51Richard Höglund

Multidrug-resistant genotypes are associated with therapeutic failure of antimalarial therapy in Cambodia; a pharmacometric approach

Thursday 15:25-16:50

IV-52Nick Holford

Rational dosing of caffeine using target concentration intervention to improve treatment of apnea of prematurity

Thursday 15:25-16:50

IV-53Chih-hsuan Hsin

Impact of intestinal and renal membrane transporter ABCB1 gene polymorphisms on the pharmacokinetics of digoxin in healthy Caucasian subjects

Thursday 15:25-16:50

IV-54Ka Ho, Matthew Hui

Evaluation of Parameter Estimation when Fitting a Mixture Model with Covariate Effects using NONMEM

Thursday 15:25-16:50

IV-55Ziad Hussein

Population Pharmacokinetics of Lemborexant, a Dual Orexin Receptor Antagonist, in Healthy Adult and Elderly Subjects and Subjects with Primary Insomnia

Thursday 15:25-16:50

IV-56Eman Ibrahim

Obesity and NAFLD activity score increase rate of fibrosis progression in a continuous-time Markov modelling of fibrosis progression in a long-term follow-up biopsy NAFLD cohort.

Thursday 15:25-16:50

IV-57Hiroyuki Iida

Modelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice

Thursday 15:25-16:50

IV-58Luis Ilia

Quantitative comparison of in vitro and in vivo variability of microdialysis experiments using nonlinear mixed-effects modelling on the example of linezolid

Thursday 15:25-16:50

IV-59Khalid Iqbal

Modelling tissue pharmacokinetics: A comparison of empiric and mechanistic PBPK modelling approaches of different complexity exemplified with moxifloxacin

Thursday 15:25-16:50

IV-60Itziar Irurzun-Arana

ACESO (A Cancer Evolution Simulation Optimizer)

Thursday 15:25-16:50

IV-61Kris Oliver Jalusic

Pharmacokinetics of vancomycin in the cerebrospinal fluid in critically ill patients

Thursday 15:25-16:50

IV-62Petra Jauslin

Modeling bounded scales for evaluation of treatment response to subcutaneous nemolizumab in moderate to severe atopic dermatitis

Thursday 15:25-16:50

IV-64Jin Jin

Model-informed artificial intelligence (AI) solution enabling real-time predictions: towards next generation modeling

Thursday 15:25-16:50

IV-65Mats Jirstrand

A challenge model of TNFα turnover with LPS provocations and drug intervention

Thursday 15:25-16:50

IV-66

M-EASE-2: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus (T1DM)

Thursday 15:25-16:50

IV-67Daniel Jonker

The impact of septic shock on the pharmacokinetics and pharmacodynamics of selepressin

Thursday 15:25-16:50

IV-68Felix Jost

Application of a feedback optimal control algorithm to a population pharmacokinetic-pharmacodynamic model of cytarabine-derived and lenograstim-reduced myelosuppression in acute myeloid leukemia

Thursday 15:25-16:50

IV-69Fabian Jung

Simulation of the environmental exposure to fenofibrate nanomaterials based on in vitro- and in silico methods

Thursday 15:25-16:50

IV-70Wannee kantasiripitak

A population pharmacokinetic and exposure-response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis

Thursday 15:25-16:50

IV-71Evangelos Karakitsios

A methodology to estimate population pharmacokinetic parameters from aggregate concentration-time data and its application to gevokizumab.

Thursday 15:25-16:50

IV-72Vangelis Karalis

An In Vitro – In Vivo Simulation Methodology for Predicting the Outcome of Bioequivalence Studies

Thursday 15:25-16:50

IV-73Eleni Karatza

Investigation of the impact of population parameters describing gastric emptying on bioequivalence metrics

Thursday 15:25-16:50

IV-74Tatiana Karelina

Amyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects

Thursday 15:25-16:50

IV-75Adrien Tessier

Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part I – simulation study evaluating type I error and power of proof-of-concept trials

Thursday 15:25-16:50

IV-76Hidefumi Kasai

Tumor Response Index (TRI): model-based prediction of tumor response and survival in metastatic colorectal cancer patients treated by mFOLFOX6 with bevacizumab

Thursday 15:25-16:50

IV-77Takayuki Katsube

Evaluation of Variance-based Global Sensitivity Analysis for Covariate Effects

Thursday 15:25-16:50

IV-78Aida Kawuma

Dolutegravir pharmacokinetics in co-administration with rifampicin.

Thursday 15:25-16:50

IV-79Ron Keizer

Continuous learning in model-informed precision dosing: a case study

Thursday 15:25-16:50

IV-80Zackary Kenz

Inflammation and Fibrosis in Nonalcoloholic Steatohepatitis (NASH) Characterized by a Mathematical Model

Thursday 15:25-16:50

IV-81Yun Kim

A population pharmacokinetic/pharmacodynamic analysis of rosuvastatin according to OATP1B1 and BCRP polymorphisms in young and elderly subjects

Thursday 15:25-16:50

IV-82NaYoung Kim

Development of predictive model for acute kidney injury after minimally invasive partial nephrectomy

Thursday 15:25-16:50

IV-83Seoyoung Kim

Population Pharmacokinetic-Pharmacodynamic Modeling of Escitalopram in Patients with Obsessive-Compulsive Disorder Using Yale-Brown Obsessive Compulsive Scale

Thursday 15:25-16:50

IV-84Dohyun Kim

Optimization of dosing strategy for Colistin using population pharmacokinetic model based on the Bayesian inference

Thursday 15:25-16:50

IV-85Lena Klopp-Schulze

Exposure-response analyses of the bifunctional fusion protein bintrafusp alfa (M7824) in early drug development

Thursday 15:25-16:50

IV-86Franziska Isabelle Kluwe

Model-based characterisation of nonlinear voriconazole pharmacokinetics following two different routes of administration

Thursday 15:25-16:50

IV-87Lisa Alina Kneller

Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on Risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach

Thursday 15:25-16:50

IV-88Stephan Koehne-Voss

A comparison of relative exposure estimates from single trough, multiple trough, and full population PK sampling designs

Thursday 15:25-16:50

IV-89Galina Kolesova

Application of different approaches to generate virtual patient populations for QSP model of Physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies

Thursday 15:25-16:50